Trial intelligence / Profile preview

Hydroxyurea and transfusion interval evaluation in pediatric beta-thalassemia major

IRCT20180707040371N1Phase 2Completed

Sponsor
Golestan University of Medical Sciences
Start
Sep 2017
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 2, open-label, single-arm trial of hydroxyurea in beta thalassemia, sponsored by Golestan University of Medical Sciences. Primary endpoints: Total hemoglobin level increase, Liver enzyme changes and 3 more. Started Sep 2017; status: completed.

02

Drugs

hydroxyurea
03

Conditions

beta thalassemia

Beyond the preview

Go deeper on IRCT20180707040371N1.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on IRCT20180707040371N1.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call